CIK 0001618835
- Non-accelerated filer
- Smaller reporting company
Evofem Biosciences, Inc.
Sign in to watch- Ticker
- EVFM
- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 208527075
- Phone
- +1 858-550-1900
- Business address
- 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO, CA, 92130
- Former names
- Neothetics, Inc.
- 4 Shares withheld for taxes Chief Financial Officer gave up 8,420 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Executive Officer gave up 16,905 shares (to pay taxes)
- 4 Shares withheld for taxes General Counsel and Secretary gave up 7,802 shares (to pay taxes)
- 4 Open-market sale Chief Medical Officer sold 2,000 shares at an average $4.71 ($9,410)
- 4 Option exercise Director acquired 37,500 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Medical Officer sold 1,000 shares at $7.00 ($7,000)
- 4 Open-market sale Chief Commercial Officer sold 14,957 shares at $6.50 ($97,221)
- 4 Grant or award Chief Commercial Officer acquired 150,899 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 303,846 shares (grant or award)
- 4 Grant or award General Counsel and Secretary acquired 150,000 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 153,846 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 153,688 shares (grant or award)
- 4 Open-market sale Chief Commercial Officer sold 1,578 shares at $6.50 ($10,257)
- 4 Open-market sale Chief Financial Officer sold 1,648 shares at $6.00 ($9,888)
- 4 Open-market sale Chief Executive Officer sold 3,295 shares at $6.00 ($19,770)
- 4 Open-market sale Chief Executive Officer sold 6,705 shares at $6.05 ($40,565)
- 4 Open-market sale Chief Financial Officer sold 3,352 shares at $6.05 ($20,280)
- 4 Option exercise Director acquired 37,500 shares (option exercise)
Page 5 of 15 · 281 filings